Actively Recruiting
Thailand Registry for Transthyretin Amyloid Cardiomyopathy Studying Symptoms, Heart Imaging, and Treatment Outcomes
Led by Mahidol University · Updated on 2025-05-08
105
Participants Needed
8
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a registry study in Thailand to observe the natural progression, clinical features, and imaging results of patients diagnosed with Transthyretin Amyloid Cardiomyopathy ATTR-CM. The goal is to gain a deeper understanding of this condition to help with early detection and raise awareness among doctors outside cardiology. With new amyloid-specific treatments now available in Thailand, this study also aims to support epidemiological research in the region. The study involves patients diagnosed with ATTR-CM, whether they show symptoms or not, confirmed through specific heart imaging tests such as echocardiograms, scintigraphy scans, and cardiac MRI. There is no intervention or treatment provided as part of this observational registry instead, participants are closely monitored over time. This study will track important events like rates of death and hospitalizations due to heart failure over a three-year period. Participants will be followed for three years with regular data collection on their health status, medication use, and hospital visits. Assessments include heart imaging and clinical evaluations to observe disease progression and treatment patterns. The main outcomes measured are death and heart failure hospitalizations, with secondary focus on medication usage for ATTR amyloidosis. This information will help improve understanding and management of ATTR-CM in Thailand.
CONDITIONS
Brief Title
Thailand ATTR-CM Registry
Research Team
K
Kanchalaporn Jirataiporn, B.N.S.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here